

INTRODUCTION	XXI
STUDY GOALS AND OBJECTIVES.....	XXI
REASONS FOR DOING THIS STUDY	XXI
CONTRIBUTIONS TO THE STUDY AND FOR WHOM.....	XXI
SCOPE AND FORMAT	XXI
METHODOLOGY	XXII
INFORMATION SOURCES.....	XXII
ABOUT THE AUTHOR.....	XXII
RELATED BCC REPORTS	XXII
BCC RESEARCH ONLINE SERVICES	XXII
DISCLAIMER	XXIII
 SUMMARY.....	 XXIV
<i>SUMMARY TABLE GLOBAL PAIN-MANAGEMENT MARKET,</i> <i>THROUGH 2012 (\$ BILLIONS)</i>	 XXV
<i>SUMMARY FIGURE SHARE OF GLOBAL PAIN-MANAGEMENT</i> <i>MARKET, BY SEGMENT 2007 AND 2012 (%)</i>	 XXV
 OVERVIEW	 1
OVERVIEW.....	1
OVERVIEW (CONTINUED)	2
<i>FIGURE 1 PAIN-MANAGEMENT TECHNIQUES</i>	3
 PAIN-MANAGEMENT MARKET	 4
WHAT IS PAIN?	4
THE PERCEPTION OF PAIN	4
TYPES OF PAIN.....	5
ACUTE PAIN	5
CHRONIC PAIN	5
TYPES OF PAIN-MANAGEMENT MEDICATIONS	6
NSAID.....	6
Side Effects of NSAIDs.....	7
<i>TABLE 1 COMMONLY USED NSAIDS</i>	7
OPIOIDS.....	7
<i>TABLE 2 CLASSES AND EXAMPLES OF OPIOIDS, DEPENDING ON</i> <i>ORIGIN</i>	8
<i>TABLE 2 (CONTINUED)</i>	9
Side Effects of Opioids.....	9
ANTICONVULSANTS.....	10
<i>TABLE 3 COMMONLY USED ANTICONVULSANTS IN PAIN</i> <i>MANAGEMENT</i>	10
ANTIDEPRESSANTS.....	11
<i>TABLE 4 COMMONLY USED ANTIDEPRESSANTS IN PAIN</i> <i>MANAGEMENT</i>	12

WORLD HEALTH ORGANIZATION PAIN LADDER	12
<i>FIGURE 2 WHO ANALGESIC LADDER</i>	13
TYPES OF PAIN BY APPLICATION	14
BURN PAIN	14
Challenges Associated with Burn Pain	15
Burn Pain Management	16
<i>FIGURE 3 BURN PAIN-MANAGEMENT APPROACH</i>	16
CANCER PAIN.....	17
<i>FIGURE 4 CAUSES OF CANCER PAIN</i>	18
Types of Cancer Pain.....	19
Pain Management in Cancer.....	20
<i>TABLE 5 CANCER PAIN MEDICATION</i>	20
Description of Some of Key Medications for Cancer	
Pain Control.....	21
Morphine.....	21
Fentanyl.....	21
Hydromorphone.....	22
Methadone	22
Buprenorphine	22
Oxycodone.....	22
Diamorphine.....	22
DENTAL PAIN.....	22
Treatment for Dental Pain	23
Acetaminophen	23
NSAIDs.....	24
COX-2 Inhibitors.....	24
Opioids.....	24
PEDIATRIC PAIN.....	24
Pediatric Pain (Continued).....	25
Pediatric Pain Treatment.....	26
<i>TABLE 6 PEDIATRIC PAIN MANAGEMENT</i>	26
HEADACHE PAIN.....	27
Types of Headache.....	27
Primary Headache	27
Tension Headache.....	27
Migraine.....	28
<i>FIGURE 5 PHASES IN MIGRAINES</i>	29
Cluster Headache.....	29
Secondary Headache.....	30
Pain Management for Headaches	30
Pain Relief or Analgesics	30
Preventive Medication.....	31
Abortive Medications	31
<i>TABLE 7 PAIN MANAGEMENT IN HEADACHES</i>	31

<i>TABLE 7 (CONTINUED)</i>	32
NEUROPATHIC PAIN	32
Neuropathic Pain (Continued)	33
Neuropathic Pain (Continued)	34
<i>FIGURE 6 MANAGEMENT OF NEUROPATHIC PAIN</i>	35
OBSTETRICAL PAIN.....	36
Obstetric Pain Management	37
Regional Anesthesia	38
SURGICAL PAIN.....	39
Pain Management in Surgery	39
<i>TABLE 8 SURGICAL PAIN MANAGEMENT</i>	40
<i>TABLE 8 (CONTINUED)</i>	41
MUSCULOSKELETAL PAIN	41
Arthritis	41
Lower Back Pain.....	42
Musculoskeletal Pain Management.....	42
<i>TABLE 9 TREATMENT OPTIONS FOR MUSCULOSKELETAL PAIN</i>	42
<i>TABLE 9 (CONTINUED)</i>	43
PAIN-MANAGEMENT MARKET ANALYSIS	44
<i>TABLE 10 HEALTHCARE DEMOGRAPHICS OF OECD COUNTRIES</i>	44
<i>TABLE 10 (CONTINUED)</i>	45
METHODS THAT PROVIDE PAIN RELIEF.....	45
<i>FIGURE 7 PAIN MANAGEMENT METHODS</i>	46
PAIN-MANAGEMENT MARKET.....	46
<i>TABLE 11 GLOBAL PAIN-MANAGEMENT MARKET, THROUGH 2012</i> (\$ BILLIONS).....	47
<i>FIGURE 8 GLOBAL PAIN-MANAGEMENT MARKET, 2005-2012</i>	47
PHARMACEUTICALS PAIN MANAGEMENT.....	48
<i>TABLE 12 GLOBAL PHARMACEUTICALS PAIN-MANAGEMENT</i> <i>MARKET FORECAST, THROUGH 2012 (\$ BILLIONS)</i>	48
<i>FIGURE 9 GLOBAL PHARMACEUTICALS PAIN-MANAGEMENT</i> <i>MARKET FORECAST, 2005–2012 (\$ BILLIONS)</i>	49
MEDICAL DEVICES PAIN MANAGEMENT.....	49
<i>TABLE 13 GLOBAL MEDICAL DEVICES PAIN-MANAGEMENT</i> <i>MARKET FORECAST, THROUGH 2012 (\$ MILLIONS)</i>	50
<i>FIGURE 10 GLOBAL MEDICAL DEVICES PAIN-MANAGEMENT</i> <i>MARKET FORECAST, 2005–2012 (\$ MILLIONS)</i>	50
PHARMACEUTICALS PAIN-MANAGEMENT MARKET ANALYSIS	51
GLOBAL PHARMACEUTICAL PAIN-MANAGEMENT MARKET	51
<i>TABLE 14 GLOBAL PHARMACEUTICALS PAIN-MANAGEMENT</i> <i>MARKET FORECAST, THROUGH 2012 (\$ BILLIONS)</i>	51
<i>FIGURE 11 GLOBAL PHARMACEUTICALS PAIN-MANAGEMENT</i> <i>MARKET FORECAST, 2005-2012 (\$ BILLIONS)</i>	52

<i>TABLE 15 GLOBAL PHARMACEUTICALS PAIN-MANAGEMENT</i>	
<i>MARKET BY TYPE, 2007 AND 2012 (%)</i>	53
<i>FIGURE 12 GLOBAL PHARMACEUTICALS PAIN-MANAGEMENT</i>	
<i>MARKET, 2007 (%)</i>	53
<i>FIGURE 13 GLOBAL PHARMACEUTICALS PAIN-MANAGEMENT</i>	
<i>MARKET, 2012 (%)</i>	54
<i>MARKET ANALYSIS BY APPLICATION</i>	55
<i>TABLE 16 GLOBAL PHARMACEUTICALS PAIN-MANAGEMENT</i>	
<i>MARKET FORECAST BY APPLICATION, THROUGH 2012 (\$</i>	
<i>BILLIONS)</i>	55
<i>TABLE 16 (CONTINUED)</i>	56
<i>TABLE 17 GLOBAL PHARMACEUTICALS PAIN-MANAGEMENT</i>	
<i>MARKET SHARES BY APPLICATION, 2007 AND 2012 (%)</i>	57
<i>FIGURE 14 GLOBAL PHARMACEUTICALS PAIN-MANAGEMENT</i>	
<i>MARKET SHARES BY APPLICATION, 2007 (%)</i>	58
<i>FIGURE 15 GLOBAL PHARMACEUTICALS PAIN-MANAGEMENT</i>	
<i>MARKET SHARES BY APPLICATION, 2012 (%)</i>	58
<i>GEOGRAPHIC MARKET ANALYSIS</i>	59
<i>TABLE 18 GLOBAL PHARMACEUTICALS PAIN-MANAGEMENT</i>	
<i>MARKET BY REGION, THROUGH 2012 (\$ BILLIONS)</i>	59
<i>FIGURE 16 GLOBAL PHARMACEUTICALS PAIN-MANAGEMENT</i>	
<i>MARKET BY REGION, 2005-2012 (\$ BILLIONS)</i>	60
<i>GEOGRAPHIC DISTRIBUTION</i>	60
<i>TABLE 19 GLOBAL PHARMACEUTICALS PAIN-MANAGEMENT</i>	
<i>MARKET SHARES, BY REGION (%)</i>	61
<i>FIGURE 17 GLOBAL PHARMACEUTICALS PAIN-MANAGEMENT</i>	
<i>MARKET SHARES, BY REGION, 2007 (%)</i>	61
<i>FIGURE 18 GLOBAL PHARMACEUTICALS PAIN-MANAGEMENT</i>	
<i>MARKET SHARES, BY REGION, 2012 (%)</i>	62
<i>U.S. PHARMACEUTICALS PAIN-MANAGEMENT MARKET</i>	62
<i>TABLE 20 U.S. PHARMACEUTICALS PAIN-MANAGEMENT MARKET,</i>	
<i>THROUGH 2012 (\$ BILLIONS)</i>	62
<i>FIGURE 19 U.S. PHARMACEUTICALS PAIN-MANAGEMENT</i>	
<i>MARKET, 2005-2012 (\$ BILLIONS)</i>	63
<i>EUROPEAN PHARMACEUTICALS PAIN-MANAGEMENT MARKET</i>	63
<i>TABLE 21 EUROPEAN PHARMACEUTICALS PAIN-MANAGEMENT</i>	
<i>MARKET, THROUGH 2012 (\$ BILLIONS)</i>	64
<i>FIGURE 20 EUROPEAN PHARMACEUTICALS PAIN-MANAGEMENT</i>	
<i>MARKET, 2005-2012 (\$ BILLIONS)</i>	64
<i>REST-OF-WORLD PHARMACEUTICALS PAIN-MANAGEMENT</i>	
<i>MARKET</i>	65
<i>TABLE 22 REST-OF-WORLD PHARMACEUTICALS PAIN-</i>	
<i>MANAGEMENT MARKET, THROUGH 2012 (\$ BILLIONS)</i>	65

<i>FIGURE 21 REST-OF-WORLD PHARMACEUTICALS PAIN-</i>	
<i>MANAGEMENT MARKET, 2005-2012 (\$ BILLIONS)</i>	66
COMPETITIVE STRUCTURE.....	66
TYPE OF COMPETITION.....	66
TIERS OF COMPETITION	67
MERGERS AND ACQUISITIONS.....	67
<i>TABLE 23 KEY MERGERS AND ACQUISITIONS</i>	67
<i>TABLE 23 (CONTINUED)</i>	68
<i>TABLE 23 (CONTINUED)</i>	69
END-USER GROUPS	69
DISTRIBUTION STRUCTURE.....	69
COMPETITIVE FACTORS.....	70
PRODUCT PIPELINE	70
<i>TABLE 24 PAIN-MANAGEMENT DRUG PRODUCT PIPELINES</i>	70
<i>TABLE 24 (CONTINUED)</i>	71
<i>TABLE 24 (CONTINUED)</i>	72
<i>TABLE 24 (CONTINUED)</i>	73
NON-OPIOID ANALGESIC MARKET	74
THE NSAIDS MARKET	74
<i>TABLE 25 TYPES OF NSAIDS USED IN PAIN MANAGEMENT</i>	75
KEY CHALLENGES.....	75
<i>TABLE 26 KEY CHALLENGES OF NSAID USE</i>	76
The Fallout Due to the Vioxx and Bextra Recall	76
Relief Only for Mild to Moderate Pain.....	76
Side Effects Such as Gastric Ulcers and Bleeding	76
COX Inhibitors Will Replace Traditional NSAID Market	
Shares	77
PRODUCT ANALYSIS	77
THE NSAIDS	77
<i>TABLE 27 OTC AND PRESCRIPTION NSAIDS</i>	77
<i>TABLE 27 (CONTINUED)</i>	78
<i>TABLE 28 NSAIDS AND THEIR USES</i>	79
TRIPTANS.....	80
<i>TABLE 29 KEY TRIPTANS AVAILABLE</i>	80
ACETAMINOPHEN.....	80
THE COX-2 INHIBITORS.....	81
<i>TABLE 30 COX INHIBITORS</i>	82
CHALLENGES FACED BY THE COX INHIBITOR MARKET	82
The Vioxx Recal—Still Fresh in Mind	82
Only One Product Available in the U.S.....	83
Uncertainty and Delay in the Launch of New COXs	83
High Prices Lead to Reluctance Among Physicians.....	83
MARKET ANALYSIS OF COX INHIBITORS.....	83
<i>TABLE 31 SALES OF COX-2 INHIBITORS, 2002–2006 (\$ BILLIONS)</i>	84

MARKET ANALYSIS	84
TABLE 32 GLOBAL NON-OPIOID PAIN-MANAGEMENT MARKET, THROUGH 2012 (\$ BILLIONS)	84
FIGURE 22 GLOBAL NON-OPIOID PAIN-MANAGEMENT MARKET, 2005-2012 (\$ BILLIONS).....	85
NON-OPIOID MARKET BY REGION	86
TABLE 33 GLOBAL NON-OPIOIDAL PAIN-MANAGEMENT MARKET BY REGION, 2007 AND 2012 (%).....	86
FIGURE 23 GLOBAL NON-OPIOIDAL PAIN-MANAGEMENT MARKET BY REGION, 2007 (%).....	87
FIGURE 24 GLOBAL NON-OPIOIDAL PAIN-MANAGEMENT MARKET BY REGION, 2012 (%).....	87
COMPETITIVE STRUCTURE	88
MARKET SHARE ANALYSIS.....	89
TABLE 34 GLOBAL NON-OPIOID PAIN-MANAGEMENT MARKET SHARES ANALYSIS, 2006 (%).....	89
FIGURE 25 GLOBAL NON-OPIOID PAIN-MANAGEMENT MARKET SHARES ANALYSIS, 2006 (%).....	90
THE OPIOIDS MARKET	91
KEY CHALLENGES.....	91
TABLE 35 KEY CHALLENGES FACED BY THE OPIOIDS MARKET.....	91
RISK OF ADDICTION DISCOURAGES PHYSICIANS TO PRESCRIBE OPIOIDS	91
LEGAL RISKS INVOLVED WITH PRESCRIPTION OF OPIOIDS	92
RISK OF POTENTIAL PATIENT ABUSE	92
SIDE EFFECTS CAUSED BY THE USE OF OPIOIDS DISCOURAGE PATIENTS AS WELL AS PHYSICIANS	92
LACK OF KNOWLEDGE IN USE AND PRESCRIPTION OF OPIOIDS	92
LOSS OF SOME KEY PATENTS WILL LEAD TO THE ENTRY OF GENERICS	93
PRODUCT ANALYSIS	93
TABLE 36 CLASSES OF OPIOIDS.....	93
TABLE 37 COMMON OPIOIDS AVAILABLE	94
COMBINATION OPIOIDS	95
TABLE 38 COMMON COMBINATION OPIOIDS AVAILABLE	95
MARKET ANALYSIS	95
TABLE 39 GLOBAL OPIOID PAIN-MANAGEMENT MARKET, THROUGH 2012 (\$ BILLIONS)	96
FIGURE 26 GLOBAL OPIOID PAIN-MANAGEMENT MARKET, 2005- 2012 (\$ BILLIONS).....	96
OPIOID MARKET BY REGION.....	97

TABLE 40 GLOBAL OPIOID PAIN-MANAGEMENT MARKET, 2007 AND 2012 (%).....	97
FIGURE 27 GLOBAL OPIOID PAIN-MANAGEMENT MARKET BY REGION, 2007 (%).....	98
FIGURE 28 GLOBAL OPIOID PAIN-MANAGEMENT MARKET BY REGION, 2012 (%).....	98
COMPETITIVE STRUCTURE.....	99
MARKET SHARE ANALYSIS.....	99
TABLE 41 GLOBAL OPIOID PAIN-MANAGEMENT MARKET SHARE ANALYSIS (%).....	100
FIGURE 29 GLOBAL OPIOID PAIN-MANAGEMENT MARKET SHARES, 2006 (%).....	100
THE ANTIDEPRESSANTS MARKET	101
CHALLENGES FACED BY THE ANTIDEPRESSANTS MARKET	101
TABLE 42 KEY CHALLENGES IN THE ANTIDEPRESSANTS MARKET....	101
SAFETY CONCERNS PLAGUE THE USE OF ANTIDEPRESSANTS	102
THE INCREASE IN THE JUVENILE SUICIDE RATE HAS CAUSED CONCERNS	102
THE DELAY BY DRUGS TO SHOW THEIR EFFECTS.....	102
UNFAMILIAR TREATMENT GUIDELINES	102
PRODUCT ANALYSIS	102
TABLE 43 ANTIDEPRESSANTS AVAILABLE IN THE U.S.	103
MARKET ANALYSIS	104
TABLE 44 GLOBAL ANTIDEPRESSANTS PAIN-MANAGEMENT MARKET FORECAST, THROUGH 2012 (\$ BILLIONS).....	104
FIGURE 30 GLOBAL ANTIDEPRESSANTS PAIN-MANAGEMENT MARKET FORECAST, 2005-2012 (\$ BILLIONS).....	104
MARKET BY REGION	105
TABLE 45 GLOBAL ANTIDEPRESSANTS PAIN-MANAGEMENT MARKET SHARES BY REGION, 2007 AND 2012 (%).....	105
FIGURE 31 GLOBAL ANTIDEPRESSANTS PAIN-MANAGEMENT MARKET SHARES BY REGION, 2007 (%).....	106
FIGURE 32 GLOBAL ANTIDEPRESSANTS PAIN-MANAGEMENT MARKET SHARES BY REGION, 2012 (%).....	106
COMPETITIVE STRUCTURE.....	107
MARKET SHARE ANALYSIS.....	107
TABLE 46 GLOBAL ANTIDEPRESSANTS MARKET SHARE ANALYSIS, 2006 (%).....	108
FIGURE 33 GLOBAL ANTIDEPRESSANTS MARKET SHARE ANALYSIS, 2006 (%).....	108
ANTICONVULSANTS MARKET	109
KEY CHALLENGES.....	109

VERY FEW APPROVALS	109
INTRODUCTION OF GENERIC COMPOUNDS	109
PRODUCT ANALYSIS	110
<i>TABLE 47 ANTICONVULSANTS AVAILABLE IN THE U.S.</i>	110
MARKET ANALYSIS	111
<i>TABLE 48 GLOBAL ANTICONVULSANTS PAIN-MANAGEMENT</i>	
<i>MARKET, THROUGH 2012 (\$ BILLIONS)</i>	111
<i>FIGURE 34 GLOBAL ANTICONVULSANTS PAIN-MANAGEMENT</i>	
<i>MARKET, 2005-2012 (\$ BILLIONS)</i>	112
MARKET BY REGION	113
<i>TABLE 49 GLOBAL ANTICONVULSANTS PAIN-MANAGEMENT</i>	
<i>MARKET BY REGION, 2007 AND 2012 (%)</i>	113
<i>FIGURE 35 GLOBAL ANTICONVULSANTS PAIN-MANAGEMENT</i>	
<i>MARKET BY REGION, 2007 (%)</i>	114
<i>FIGURE 36 GLOBAL ANTICONVULSANTS PAIN-MANAGEMENT</i>	
<i>MARKET BY REGION, 2012</i>	114
COMPETITIVE STRUCTURE	115
MARKET SHARE ANALYSIS	115
<i>TABLE 50 GLOBAL ANTICONVULSANTS PAIN-MANAGEMENT</i>	
<i>MARKET SHARE ANALYSIS, 2006 (%)</i>	115
<i>FIGURE 37 GLOBAL ANTICONVULSANTS PAIN-MANAGEMENT</i>	
<i>MARKET SHARE ANALYSIS, 2006 (%)</i>	116
MEDICAL DEVICES FOR PAIN MANAGEMENT	117
KEY DRIVERS	117
<i>TABLE 51 KEY DRIVERS FOR THE PAIN-MANAGEMENT DEVICES</i>	
<i>MARKET</i>	118
TYPES OF DEVICES USED IN PAIN MANAGEMENT	118
<i>FIGURE 38 MEDICAL DEVICES USED IN PAIN MANAGEMENT</i>	119
SPINAL CORD STIMULATOR AND PERIPHERAL NERVE	
STIMULATORS	119
Spinal Cord Stimulator and ...(Continued)	120
TRANSCUTANEOUS ELECTRICAL NERVE MUSCLE	
STIMULATOR	121
INTRATHECAL PUMPS AND PATIENT CONTROLLED	
ANALGESIA	122
Intrathecal Pumps and ...(Continued)	123
Intrathecal Pumps and ...(Continued)	124
OTHER DEVICES USED IN PAIN MANAGEMENT	125
MARKET ANALYSIS	125
<i>TABLE 52 MEDICAL DEVICES PAIN-MANAGEMENT MARKET,</i>	
<i>THROUGH 2012 (\$ MILLIONS)</i>	125
<i>FIGURE 39 MEDICAL DEVICES PAIN-MANAGEMENT MARKET,</i>	
<i>2005-2012 (\$ MILLIONS)</i>	126
MARKET ANALYSIS BY TYPE	127

TABLE 53 MEDICAL DEVICES PAIN-MANAGEMENT MARKET BY SEGMENT (%).....	128
FIGURE 40 MEDICAL DEVICES PAIN-MANAGEMENT MARKET BY SEGMENT, 2007 (%).....	128
FIGURE 41 MEDICAL DEVICES PAIN-MANAGEMENT MARKET BY SEGMENT, 2012 (%).....	129
MARKET ANALYSIS BY REGION	129
TABLE 54 MEDICAL DEVICES PAIN-MANAGEMENT MARKET BY REGION, THROUGH 2012 (\$ MILLIONS)	130
FIGURE 42 MEDICAL DEVICES PAIN-MANAGEMENT MARKET BY REGION, 2005-2012 (\$ MILLIONS).....	130
TABLE 55 MEDICAL DEVICES PAIN-MANAGEMENT MARKET SHARES BY REGION, 2007 AND 2012 (%)	131
FIGURE 43 MEDICAL DEVICES PAIN-MANAGEMENT MARKET SHARES, BY REGION, 2007 (%).....	131
FIGURE 44 MEDICAL DEVICES PAIN-MANAGEMENT MARKET SHARES BY REGION, 2012 (%).....	132
COMPETITIVE STRUCTURE	132
Types of Competition	132
Tiers of Competition	133
MERGERS AND ACQUISITIONS.....	133
Advanced Neuromodulation Systems and St. Jude Medical.....	133
Advanced Bionics Corp. and Boston Scientific.....	133
Empi, Inc. and Encore Medical Corp.	133
ADJUVANT TREATMENT METHODS FOR PAIN MANAGEMENT	134
ACUPUNCTURE	134
ACUPUNCTURE (CONTINUED).....	135
ACUPRESSURE	136
BIOFEEDBACK.....	137
HEADACHE	138
Migraine.....	138
Other Headaches	139
GENERAL PAIN	139
HYPNOSIS.....	139
APPLICATION OF HYPNOSIS	140
MUSIC THERAPY	141
LASER THERAPY	142
MASSAGE THERAPY	143
REGULATIONS AND KEY ISSUES IN PAIN MANAGEMENT	144
ROLE OF REGULATIONS IN PAIN MANAGEMENT.....	144
DEA SCHEDULE OF CONTROLLED SUBSTANCES.....	145
TABLE 56 DEA SCHEDULE OF CONTROLLED SUBSTANCES	145

<i>TABLE 56 (CONTINUED)</i>	146
THE NATIONAL PAIN CARE POLICY ACT (H.R. 1020)	146
THE NATIONAL PAIN CARE POLICY ACT (CONTINUED).....	147
IMPACT OF THE NATIONAL PAIN POLICY OF 2005	148
BARRIERS TO CANCER PAIN	148
FEAR OF ADDICTION.....	149
FEAR OF SIDE EFFECTS	149
INADEQUATE PAIN ASSESSMENT	149
INADEQUATE KNOWLEDGE/TRAINING	149
LEGAL HASSLES.....	149
PROBLEMS RELATED TO THE HEALTHCARE SYSTEM	150
THE PAIN CONSORTIUM	150
VIOXX RECALL.....	151
<i>TABLE 57 IMPACTS OF THE VIOXX RECALL</i>	152
THE OXYCONTIN ISSUE	152
The OxyContin Issue (Continued)	153
<i>TABLE 58 IMPACT OF OXYCONTIN ABUSE</i>	154
COMPANY PROFILES	155
ABBOTT LABORATORIES.....	155
ASTRAZENECA.....	156
BAYER HEALTHCARE	157
BIOVAIL CORP.	158
ELI LILLY AND CO.	159
ENCORE MEDICAL.....	159
ENDO PHARMACEUTICALS	160
GLAXOSMITHKLINE, PLC	161
JAVELIN PHARMACEUTICALS.....	162
JOHNSON & JOHNSON	163
MEDTRONICS, INC.....	164
MERCK & CO., INC.	165
NOVARTIS.....	166
PURDUE PHARMACEUTICALS	167
ROCHE.....	168
SANOFI-AVENTIS	169
ST. JUDE MEDICAL.....	170
PATENT ANALYSIS	171
GENERAL TRENDS.....	171
<i>TABLE 59 NUMBER OF U.S. PATENTS FILED FOR THE FOUR</i>	
<i>MAJOR SEGMENTS, 1997–2006</i>	171
<i>FIGURE 45 NUMBER OF U.S. PATENTS FILED FOR THE FOUR</i>	
<i>MAJOR SEGMENTS, 1997–2006</i>	172
PATENT ANALYSES	172
NSAIDS	172

TABLE 60 NSAID PATENT DISTRIBUTION, BY YEAR, 1997-2006 (NUMBER OF PATENTS)	173
FIGURE 46 NSAID PATENT DISTRIBUTION BY YEAR, 1997-2006 (NUMBER OF PATENTS)	173
OPIOIDS	173
TABLE 61 OPIOID PATENT DISTRIBUTION BY YEAR, 1997-2006 (NUMBER OF PATENTS)	174
FIGURE 47 OPIOID PATENT DISTRIBUTION BY YEAR, 1997-2006 (NUMBER OF PATENTS)	174
PAIN-MANAGEMENT MEDICAL DEVICES	174
TABLE 62 PAIN-MANAGEMENT MEDICAL DEVICE PATENTS BY ASSIGNEE COUNTRY	175
FIGURE 48 PAIN-MANAGEMENT MEDICAL DEVICE PATENTS BY ASSIGNEE COUNTRY (NUMBER OF PATENTS)	175
TRENDS BY COMPANY	176
TABLE 63 U.S. PATENTS FILED BY ASSIGNEE COMPANY, 1997-2006....	176
FIGURE 49 U.S. PATENTS FILED BY ASSIGNEE COMPANY, 1997- 2006 (%)	177
CONCLUSIONS	177
CONCLUSIONS (CONTINUED)	178
APPENDIX A: KEY INDUSTRY WEBSITES	179
KEY REGULATORY AND INFORMATION WEBSITES	179
KEY MANUFACTURER WEBSITES	180
APPENDIX B: REVENUES OF KEY PHARMACEUTICAL COMPANIES	181
TABLE 64 REVENUES OF SOME KEY PHARMACEUTICAL COMPANIES, 2005 AND 2006 (\$ BILLIONS)	181
CURRENCY CONVERSIONS	181